We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pregnancy/Implantation Rates Using a Day 3 Score Versus Graduated Embryo Score Plus a Biochemical Marker (sHLA-G)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00680238
First Posted: May 20, 2008
Last Update Posted: May 20, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University of Stellenbosch
May 15, 2008
May 20, 2008
May 20, 2008
June 2004
June 2007   (Final data collection date for primary outcome measure)
Pregnancy and implantation rates [ Time Frame: 12 weeks ]
Same as current
No Changes Posted
  • Miscarriage rates [ Time Frame: 9 months ]
  • Miscarriage rates [ Time Frame: 9-11 day until βhCG ]
Same as current
Not Provided
Not Provided
 
Pregnancy/Implantation Rates Using a Day 3 Score Versus Graduated Embryo Score Plus a Biochemical Marker (sHLA-G)
Pregnancy and Implantation Rates When Embryos Are Selected Based on a Single Day 3 Score (Day 3)vs Graduated Embryo Score(GES) Plus Soluble Human Leukocyte Antigen-G Expression.
Objective: To compare pregnancy rates and implantation rates when embryos are selected based on a single Day 3 (D.3) score vs. a GES score plus sHLA-G expression.
Comparing pregnancy rates and implantation rates when embryos are selected using the most common criteria for embryo selection on day 3 - the morphology-(number of blastomere, their shape and size and the percentage of fragmentation)vs a graduated embryo score accumulated over 72 hours and the expression of sHLA-G at 44-46 hours post fertilization.
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Infertility
Drug: Human derived FSH
Customized for each patient
Other Name: Bravelle
  • No Intervention: A
    Embryo selection for transfer based on a Day 3 score only.
    Intervention: Drug: Human derived FSH
  • Active Comparator: B
    Embryos for transfer by first selecting any embryos that had a positive sHLA-G expression of OD = 190 ±6 and correlating such with the highest GES score available.
    Intervention: Drug: Human derived FSH
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
214
June 2007
June 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Self paying ART patients

Exclusion Criteria:

  • Abnormal uterus
  • Specific Immunologic factors
Sexes Eligible for Study: Female
25 Years to 40 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00680238
DKotze
Yes
Not Provided
Not Provided
Mr DJ Kotze, Stellenbosch University
University of Stellenbosch
Not Provided
Study Director: Thinus Kruger, M.D. PhD. University of Stellenbosch
University of Stellenbosch
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP